AZ And J&J’s Problems Fuel Demand For Pfizer and Moderna COVID-19 Vaccines
EU Increases Order For Comirnaty
Pfizer/BioNTech is emerging as the EU’s partner of choice for COVID-19 vaccines, but others could also benefit.
You may also be interested in...
The European Commission appears to be favoring mRNA vaccines in its negotiations with companies on the next generation of COVID-19 vaccine contracts. Manufacturing finally appears to be gaining momentum, and the health commissioner claims the EU has “turned the corner” with its vaccination programs.
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.